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OBJECTIVES: The objective of the analysis was to compare trends of single versus 
multiple technology appraisals (STA versus MTA) recommendations for new tech-
nologies conducted by NICE. Analysis was also conducted for products with European 
Union (EU) orphan designation. Further analysis was conducted to identify any dis-
ease areas that could be particularly challenging for companies planning a European 
launch of any new products, aiming to support planning for sequencing across the 
EU. METHODS: A longitudinal database containing all technology appraisal guidance 
published by NICE since the formation of the organization was analyzed. Analysis 
of products by disease area was conducted by classification into British National 
Formulary (BNF) categories. All published guidance was included thus reviews 
of technology appraisals, which overwrite earlier guidance, were not accounted 
for. RESULTS: In 2000-2007, the ratio of guidance published for MTAs to STAs was 
3:1 (54 versus 17). However, this ratio was reversed in 2008-2014, when guidance was 
published for 46 MTAs and 132 STAs. In 2009, 92% of STA guidance included positive 
or restricted recommendation (n= 12), decreasing to a historical low of 52% in 2013 
(n= 27) and increasing to 85% in 2014 (n= 20). 50% of recommendations for orphan 
products were positive or restricted in 2011 and 2013 (n= 6) but 100% were positive 
or restricted in 2012 and 2014 (n= 3). The overall recommendation rate is lower for 
orphan products than no-orphan products (67% versus 73%). Malignant disease and 
immunosuppression treatments were the most common STAs but had the second 
lowest recommendation rate (59%, n= 71). Cardiovascular treatments were most con-
sistently recommended (100%, n= 19). CONCLUSIONS: A decreasing proportion of 
appraisals include multiple technologies. There have been substantial variations in 
annual recommendations from STAs, possibly due to the choice of appraisal commit-
tee and evidence review group, which makes it very challenging for manufacturers 
to predict likely outcomes.
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OBJECTIVES: Data published by the Office for Health Economics in 2011 showed 
rejection from the SMC was more likely for orphan than for non-orphan prod-
ucts. Following a review of the SMC in 2012, the process for appraising end-of-life, 
orphan and ultra-orphan drugs was modified to facilitate greater access for patients 
in Scotland. We analyze if the revised SMC process has been successful in provid-
ing more positive recommendations for orphan products and which factors may 
influence the decision. METHODS: Analyses were based on a validated, longitudi-
nal database of all recommendations from 2002 to 2014. Products with a European 
Orphan designation were analysed. SMC recommendations following full submission, 
resubmission or abbreviated submission were reviewed and sub divided into British 
National Formulary (BNF) category. RESULTS: In 2002-2014, there were 8 abbreviated 
submissions to the SMC for orphan products, 68 full submissions and 25 resubmis-
sions. The positive recommendations rate (with or without restriction) from 2002-2013 
was 53% (n= 92); in 2014 this recommendation rate increased to 89% (n= 9). Up to 2013, 
malignant disease and immunosuppressive treatments accounted for 43% of the 
published guidance of orphan products with a recommendation rate of 50% (n= 40); 
in 2014 this improved to 80% (n= 5). Cardiovascular treatments have a high recom-
mendation rate of 92% (n= 13) but treatments for musculoskeletal and joint diseases 
have the lowest success with all three submissions receiving negative recommenda-
tion. In 2013, evidence for 7 orphan products was not submitted to the SMC within 
the required 3 months of license thus received automatic negative recommenda-
tion, however, this reduced to only one non-submission in 2014. CONCLUSIONS: The 
SMC recommendation rate for orphan products, particularly malignant disease and 
immunosuppressive drugs, has improved from 2013 to 2014 suggesting the revised 
SMC appraisal process may be more effective in enabling the SMC to provide positive 
recommendations for orphan products.
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OBJECTIVES: Since formation in 2002, the Scottish Medicines Consortium (SMC) has 
evaluated 608 health technology assessment (HTA) submissions of new medicines for 
use in Scotland. They have, therefore, reviewed more clinical and cost-effectiveness 
evidence for medicines than any other HTA organization in the world. Trends in 
SMC guidance were analysed to provide insights on likely recommendations of new 
products as manufacturers navigate the UK market. METHODS: All analyses were 
based on a validated, longitudinal database of all published guidance from 2002 to 
2014. SMC recommendations following full submission, resubmissions or abbreviated 
submissions were reviewed and then subdivided into British National Formulary (BNF) 
category. RESULTS: From 2002 to 2014, the SMC has published guidance following 608 
full submissions, 232 abbreviated submissions, 157 non-submissions, 158 resubmis-
sions and 5 Independent review panels. The proportion of products not recommended 
has fallen from 40% in 2007 (n= 98) to only 17% in 2014 (n= 84). Products falling into the 
malignant disease and immunosuppression BNF category were the most common 
submission to the SMC (20% of submissions, n= 197) with an approval rate steadily 
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OBJECTIVES: To describe reporting rates of gender-specific safety outcomes 
for new molecular entity (NME) drugs approved from the US Food and Drug 
Administration (US FDA) between 2009 and 2013 METHODS: New drug applica-
tion (NDA) files for all NME drugs that were approved for systemic use in men and 
women were surveyed from the US FDA database. Specific reviews and key word 
searches were made for descriptions or tabulation of gender-specific inferential 
statistics on the drug safety section. The rates of inclusion of explicit descriptions 
or reports of statistical significance were calculated. RESULTS: Of all 457 approved 
drugs during the study period, 118 NMEs were included for the evaluation. Of 
those, 8 NMEs and 13 NMEs were excluded due to gender specific indications or 
non-systemic route of administration, respectively, thereby remaining 97 NME 
drugs were further reviewed. On average, gender-specific safety outcome descrip-
tions were included in 74.2% (72/97) of the reviews. Gender-specific statistical 
significance was reported in 13% of the reviews. Format of the outcome descrip-
tions was inconsistent varying from statement in the body text to table without 
descriptions. CONCLUSIONS: About one in four NDA reviews for NMEs was lacking 
sufficient descriptions on gender-specific safety outcomes and the format of the 
safety outcome reports by gender was inconsistent.
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OBJECTIVES: Little guidance exists for healthcare professionals on how to evaluate 
and use CER studies with new unfamiliar designs or methods. To fill this gap, the 
CER Collaborative (AMCP, IPSOR, and NPC) developed task force reports and on-line 
tools. The aim of this study was to determine if a multi-media continuing educa-
tion (CE) program, largely derived from task-force reports and related online CER 
Collaborative tools, improved learner ability and confidence to assess CER studies 
for use in real-world decision-making. METHODS: Twenty healthcare profession-
als registered for a 19-hour, ACPE-approved CER Certificate Program (CCP) which 
included five self-paced, online modules and case studies: prospective and retro-
spective observational studies, indirect treatment comparisons, models, and syn-
thesizing information from studies with various designs. A final live workshop was 
conducted to enhance learner skills through case presentation and peer critique. 
After CCP completion, learners assessed their ability to evaluate CER studies using a 
Likert scale (1= strongly disagree, 5= strongly agree). RESULTS: In the first cohort of 
learners, 18 (90%) completed the program on schedule. Significant improvement in 
self-reported ability to evaluate CER study design on their relevance and credibility 
ranged from 29.17% (CI 18.50 - 39.83) to 61.76% (CI 49.08 – 74.45) at program comple-
tion. Learners indicated high confidence in their CER evidence assessment abilities 
(mean score 4.17; CI 3.93 – 4.40). CONCLUSIONS: As new or unfamiliar CER study 
designs and analyses become available, there will be an increasing need for clini-
cians and other decision-makers to understanding how to assess the relevance and 
credibility of CER studies to inform decision-making. The CER Certificate Program, 
was associated with improved healthcare decision-makers’ self-reported ability to 
evaluate CER and apply it for use in decision-making.
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OBJECTIVES: A review of the literature was conducted to determine whether there 
is an appropriate definition for market access. The original perception was that 
it relates to securing market authorization, as well as enabling prescribing of the 
product. A working definition for pharmaceutical market access was proposed as 
“a process of enabling patient access to pharmaceutical products, not only through 
gaining regulatory approval, but also through gaining an acceptable optimal price 
and reimbursement status to manufacturers and payers.” The objective of this 
survey was to determine how appropriate the proposed definition is by compar-
ing it to definitions proposed by differing professionals within the healthcare 
industry. METHODS: A review of the literature was undertaken, followed by the 
development of a questionnaire aimed at eliciting the various determinants of 
pharmaceutical market access, both from the patient and payer perspectives. This 
survey was administered to professionals in three settings involving ISPOR European 
Congress, EMAUD educational course, and a pharmaceutical company, with forty 
eight, forty five, and seventeen respondents, respectively. The respondents were 
categorized as belonging to: academia, pharmaceutical industry, healthcare pro-
fession, policy maker/Health Technology Assessment Agency (payer), and consul-
tancy. Responses were recorded verbatim, and then coded by the interviewers to 
aid analysis. RESULTS: The survey suggested there is an inadequate understanding 
of market access, and this is independent of the professional background of the 
respondent. Furthermore, there is not a consistent agreement as to what factors 
influence the successful development and commercialization of pharmaceutical 
products. CONCLUSIONS: Successful market access of pharmaceutical products 
requires a wider understanding of the role of patients and payers in the develop-
ment and commercialization by all stakeholders in the healthcare delivery system. 
Further research is needed into this field as it has important health policy implica-
tions for patient care.
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the G-BA website. 104 molecules that had gone through the AMNOG procedure were 
identified and further categorized in order to determine whether they had submit-
ted direct, indirect, or both types of comparisons. The G-BA publications by means 
of the classification score were used to source and quantify the outcome of the deci-
sion. RESULTS: 16 out of the 104 analyzed molecules were found to have submitted 
indirect comparisons. Out of these, the G-BA decisions recognized that 6 molecules 
had mild or significant overall added benefit. All of these 6 molecules presented both 
direct and indirect comparisons. On the other hand, molecules that only submitted 
indirect comparisons were found to have no additional benefit. The most common 
reasons for dismissals of indirect comparisons by IQWiG were the inappropriate 
patient population selection, the choice of inappropriate bridge comparators, and 
that population uniformity was not guaranteed. CONCLUSIONS: These results dem-
onstrate that submission of indirect comparisons alone are unlikely to result in a 
positive added benefit classification by IQWiG and the G-BA. However, if the indirect 
comparison is coupled with a direct comparison, the outcome of the assessment by 
the G-BA is more likely to result in a positive added benefit classification.
PHP142
trend analysis of g-ba deCisions – wHat faCtors influenCe tHe 
likeliHood of reCommendations?
Hill C.A., Hill D., Marshall J.D., Harries M.
MAP BioPharma Limited, Cambridge, UK
OBJECTIVES: The first step in the route to reimbursement of a new product in 
Germany through the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) process is an 
assessment of additional benefit, conducted by the Gemeinsamer-Bundesausschuss 
(G-BA), which directly influences pricing negotiations. The G-BA may classify addi-
tional benefit of a new substance as major, considerable, minor or unquantifiable 
benefit or ‘no-benefit’. The analysis was conducted to compare trends of G-BA deci-
sions for new technologies and orphan technologies. Further analysis was conducted 
to identify differences in disease areas for companies planning a European launch 
of a new product. METHODS: A longitudinal database containing all additional ben-
efit decisions made by the G-BA was analyzed. Only one decision was published 
in 2011 so only data from 2012-2014 was explored for robustness. Orphan analysis 
was conducted for products with European Union (EU) orphan designation. Analysis 
by disease area classified products into British National Formulary (BNF) catego-
ries. RESULTS: In 2012-2014, G-BA assessed 99 new technologies and decided 48% of 
products had no additional benefit, 25% had minor additional benefit, 18% had consid-
erable additional benefit and the remainder had unquantifiable additional benefit. No 
technologies have been classified as having major additional benefit. G-BA are unable 
to classify an orphan treatment has having no additional benefit due to the nature of 
orphan designation thus no ‘no-benefit’ decisions of orphan products have been made 
but the G-BA decided that 38% (n= 16) of orphan products had unquantifiable benefit 
and 19% had considerable benefit (n= 3). 34% of decisions were for malignant disease 
and immunosuppression products. 12 of the 19 products found to have considerable 
benefit were for malignant disease and immunosuppression. CONCLUSIONS: A high 
proportion of G-BA decisions have been of no or unquantifiable benefit indicating 
that obtaining a high price in Germany is challenging but more likely for orphan, 
malignant disease and immunosuppression products.
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OBJECTIVES: Information regarding health technology assessment (HTA) require-
ments for orphan drugs in Asia Oceania is limited. The aim of our study was to com-
pare HTA evidentiary requirements for standard and orphan drug appraisals among 
7 Asia Oceania countries/regions. METHODS: A literature and policy review was con-
ducted to identify standard and orphan drug HTA requirements and processes for 
the following countries: Australia, Japan, South Korea and China (further divided into 
regions including Mainland China, Hong Kong, Singapore and Taiwan to capture the 
diverse healthcare markets included in the country). A modified Hutton Framework 
was used to descriptively assess the HTA and reimbursement processes in these 
7 countries/regions. RESULTS: Authorities in Asia Oceania are currently in various 
stages of HTA and reimbursement process development for standard and orphan 
drugs. Of the 7 countries/regions studied, Australia is the only country with distinct 
orphan drug HTA evidentiary requirements and processes compared to standard 
drugs. Cost-effectiveness evidence is required as part of South Korea’s standard HTA 
review, but incremental cost-effectiveness ratio (ICER) thresholds are more lenient 
for orphan drugs. In Hong Kong, orphan drugs are assessed by an independent expert 
review committee, and appraisal criteria weigh heavily on patient characteristics and 
perceived benefit. Several countries/regions include health economics in their stand-
ard HTA review: Taiwan (budget impact, comparative effectiveness) and Singapore 
(cost-effectiveness); both countries/regions have similar evidentiary requirements 
for orphan and standard drugs. Japan is in early stages of developing HTA procedures 
and requires minimal economic evidence in standard and orphan drug assessment. 
Mainland China does not have a centralized HTA process for standard and orphan 
drugs. CONCLUSIONS: Most Asia Oceania countries/regions are still developing their 
HTA policies. Due to lack of distinct orphan drug HTA procedures in Taiwan, Singapore, 
Mainland China, and Japan, obtaining reimbursement for drugs may require addi-
tional efficacy or health economic analyses.
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decreasing from 65% in 2005 (n= 17) to 47% in 2013 (n= 15) but then drastically improv-
ing to 82% in 2014 (n= 22). The BNF category with the highest recommendation rate 
was infections (88%, n= 102); conversely, the gastro-intestinal system category had 
the lowest recommendation rate (55%, n= 42). CONCLUSIONS: Results suggest that 
HTA trends in Scotland were reformed in 2014 by changes in the SMC process, which 
included the aim of improving patient access to cancer medications. Recent changes 
implemented by SMC as a result of the Routledge review may provide hope to compa-
nies preparing to navigate the SMC process with oncology, immunology or infection 
products, but companies with products in other areas should explore all considera-
tions through further analyses to maximise market access opportunities in Scotland.
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OBJECTIVES: The Scottish Medicines Consortium (SMC) recommend the use of 
cost-minimization analysis for: therapeutically equivalent treatments established 
through non-inferiority studies; indirect comparisons showing statistically insig-
nificant difference; or where cost-utility analysis shows extremely small quality-
adjusted life year differences between treatments. When a new medicine has 
identical benefits to the comparator, the SMC chooses the cheaper option. In 2014, 
the Office for Health Economics found that whilst the SMC does not specify a type 
of economic analysis for biosimilars, cost-minimization analysis had been used for 
all approved submissions. We examine longitudinal trends and probabilities of rec-
ommendation for any companies using cost-minimization analysis. METHODS: All 
analyses were based on a validated, longitudinal database of all recommendations 
from 2002 to 2014. SMC recommendations following full submission, resubmis-
sions or abbreviated submissions were reviewed to provide some insight into the 
considerations that companies should include in their strategic plans. RESULTS: 
Since 2010, there has been an increasing trend for the use of cost-minimization 
analysis with 35% of full submissions in 2014 using cost-minimization, as well as 
25% of resubmissions. Of the 68 cost-minimization submissions, 24 have received 
positive recommendation, 35 restricted and 9 not recommended. Cost minimiza-
tion has been used in the greatest proportion of respiratory submissions (47% of 
submissions, n= 8, 88% recommended) and infections (43% of submissions, n= 6, 
100% recommended) but most cost-minimization submissions are for endocrine 
treatments (30% of submissions, n= 11, 91% recommended). The recommendation 
rates per BNF category vary greatly with no distinct category having greater suc-
cess. CONCLUSIONS: A manufacturer is most likely to gain a restricted recom-
mendation following submission of cost-minimization analysis. There is no distinct 
BNF category that has a greater chance of success using cost-minimization analysis. 
To recommend with cost-minimization analysis, the SMC must be certain that the 
comparators are appropriate and effectiveness is comparable.
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OBJECTIVES: Considering official introduction of pharmacoeconomic require-
ments in Japanese healthcare policy in 2016, we aimed to assess whether the qual-
ity of pharmacoeconomic studies in Japan has been improved over time, and what 
aspects are in need for further improvement. METHODS: The literature review 
approach was taken for English-language articles via PubMed (Japan AND “Cost-
Benefit Analysis”[Mesh]) and Embase (Japan AND cost effectiveness), and also for 
Japanese-language via Web service of Japan Medical Abstracts Society (“hiyo-tai-
koka” in Japanese, which means “cost-effectiveness”), excluding review articles, 
commentaries, methodological studies, and letters. After eligibility screening, we 
eventually obtained 174 articles as subjects, which were summarized and assessed 
regarding the quality of reporting on whether to state the five factors explicitly: 1) 
study perspective, 2) reason of discount rate, 3) year of currency, 4) time horizon, and 
5) comparator. For each of those factors, we examined a proportion of satisfaction, 
i.e., a percentage of the articles having clearly described the target factor among all 
the articles. In addition, the proportions were compared by the other nominal fac-
tors such as founding source, intervention type, and QALY employment. RESULTS: 
The number of publications has been increasing over time. Over 60 % of studies, 
however, did not clearly disclose their funding sources. The studies without any 
funding disclosure revealed less satisfaction in each of the five factors. Those with 
disclosure of industry-funding had higher satisfaction rates compared to the studies 
with public-funding disclosure or without funding disclosure. Although the stud-
ies which employed QALY as the outcome measure earned high satisfaction of the 
five factors, no totally positive improvement was observed over time in terms of 
satisfaction for any of the five factors. CONCLUSIONS: The quality of reporting the 
Japanese health economic evaluations was not yet satisfactory, and remains further 
challenges for quality improvement to comply with the international standards.
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OBJECTIVES: The AMNOG assessment procedure requires that manufacturers sub-
mit indirect comparisons for the assessment of molecules in the absence of direct 
comparisons versus the G-BA appropriate comparator. The purpose of this study 
was to understand the role that indirect comparisons have in IQWiG’s assessment 
of added benefit and consequently also on the G-BA decision outcome. METHODS: 
The IQWiG assessments and G-BA evaluations through the AMNOG process from 
initial implementation to the end of 2014 were analyzed based on publications from 
